{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the 95% confidence interval (CI) was not calculated due to the high censoring rate.","groupId":"OG000","lowerLimit":"17.72","upperLimit":"NA","value":"22.32"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"}],"units":"Participants"}],"description":"OS defined as the time from first dose date to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"200 mg abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Abemaciclib"}],"paramType":"MEDIAN","populationDescription":"All enrolled participants who received at least one dose of study drug. Censored participants: Abemaciclib=70.","reportingStatus":"POSTED","timeFrame":"From Date of First Dose until Death Due to Any Cause (Up To 27 Months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}